6ST3

HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with 4-hydroxy-N-(4-phenoxybenzyl)-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxamide

6ST3 の概要

• エントリーDOI: 10.2210/pdb6st3/pdb
• 分子名称: Egl nine homolog 1, 4-oxidanyl-~{N}-[(4-phenoxyphenyl)methyl]-2-pyrazol-1-yl-pyrimidine-5-carboxamide, FORMIC ACID, ... (5 entities in total)
• 機能のキーワード: oxidoreductase, non-heme dioxygenase, iron, 2-oxoglutarate, hypoxia-inducible factor, hif, hif prolyl hydroxylase domain 2, phd2, egln1, oxygenase, hypoxia, dna-binding, metal-binding, transcription, helix-loop-helix-beta, dsbh, facial triad, cytoplasm, transcription/epigenetic regulation, signaling, development, cell structure, beta-hydroxylation, transcription activator/inhibitor, ubl conjugation, polymorphism, vitamin c, zinc-finger, familial erythrocytosis, breast cancer, transcription complex
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 53049.87

構造登録者

Chowdhury, R.,Holt-Martyn, J.P.,Schofield, C.J. (登録日: 2019-09-10, 公開日: 2019-12-04, 最終更新日: 2024-01-24)

主引用文献

Holt-Martyn, J.P.,Chowdhury, R.,Tumber, A.,Yeh, T.L.,Abboud, M.I.,Lippl, K.,Lohans, C.T.,Langley, G.W.,Figg Jr., W.,McDonough, M.A.,Pugh, C.W.,Ratcliffe, P.J.,Schofield, C.J.
Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
Chemmedchem, 15:270-273, 2020

PubMed Abstract: The 2-oxoglutarate-dependent hypoxia inducible factor prolyl hydroxylases (PHDs) are targets for treatment of a variety of diseases including anaemia. One PHD inhibitor is approved for use for the treatment of renal anaemia and others are in late stage clinical trials. The number of reported templates for PHD inhibition is limited. We report structure-activity relationship and crystallographic studies on a promising class of 4-hydroxypyrimidine-containing PHD inhibitors.

PubMed: 31751494
DOI: 10.1002/cmdc.201900557

実験手法

X-RAY DIFFRACTION (2.426 Å)